JP2007530595A5 - - Google Patents

Download PDF

Info

Publication number
JP2007530595A5
JP2007530595A5 JP2007505245A JP2007505245A JP2007530595A5 JP 2007530595 A5 JP2007530595 A5 JP 2007530595A5 JP 2007505245 A JP2007505245 A JP 2007505245A JP 2007505245 A JP2007505245 A JP 2007505245A JP 2007530595 A5 JP2007530595 A5 JP 2007530595A5
Authority
JP
Japan
Prior art keywords
compound
agent
heteroatoms
independently
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007505245A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007530595A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/010204 external-priority patent/WO2005100342A1/en
Publication of JP2007530595A publication Critical patent/JP2007530595A/ja
Publication of JP2007530595A5 publication Critical patent/JP2007530595A5/ja
Pending legal-status Critical Current

Links

JP2007505245A 2004-03-26 2005-03-25 Ｅｒｋ２のピリジンインヒビターおよびそれらの使用 Pending JP2007530595A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55676604P 2004-03-26 2004-03-26
PCT/US2005/010204 WO2005100342A1 (en) 2004-03-26 2005-03-25 Pyridine inhibitors of erk2 and uses thereof
US11/089,701 US7462612B2 (en) 2004-03-26 2005-03-25 Pyridine inhibitors of ERK2 and uses thereof

Publications (2)

Publication Number Publication Date
JP2007530595A JP2007530595A (ja) 2007-11-01
JP2007530595A5 true JP2007530595A5 (https=) 2008-05-08

Family

ID=34964893

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007505245A Pending JP2007530595A (ja) 2004-03-26 2005-03-25 Ｅｒｋ２のピリジンインヒビターおよびそれらの使用

Country Status (4)

Country Link
US (1) US7462612B2 (https=)
EP (1) EP1730134A1 (https=)
JP (1) JP2007530595A (https=)
WO (1) WO2005100342A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008530193A (ja) * 2005-02-18 2008-08-07 アストラゼネカ アクチボラグ 化合物
US20060235028A1 (en) * 2005-04-14 2006-10-19 Li James J Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8211919B2 (en) 2005-09-02 2012-07-03 Astellas Pharma Inc. Amide derivatives as rock inhibitors
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
JP2009528280A (ja) * 2006-02-16 2009-08-06 シェーリング コーポレイション Ｅｒｋインヒビターとしてのピロリジン誘導体
RU2008148962A (ru) 2006-05-12 2010-06-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Избирательно действующие ингибиторы rоск протеинкиназы и их применение
AU2007275221A1 (en) * 2006-07-20 2008-01-24 Allen J. Borchardt Benzothiophene inhibitors of RHO kinase
EP2079739A2 (en) 2006-10-04 2009-07-22 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
CN101611007A (zh) * 2006-12-20 2009-12-23 先灵公司 新颖的jnk抑制剂
CL2008001822A1 (es) * 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
EP2192838A4 (en) * 2007-08-15 2011-07-27 Harvard College HETEROCYCLIC NEKROPTOSIS HEMMER
US8716483B2 (en) 2008-02-21 2014-05-06 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
BRPI0922435A2 (pt) 2008-12-19 2018-09-11 Sirtris Pharmaceuticals Inc "composto de tiazolopiridina moduladores de sirtuina, composição farmacêutica compreendendo o mesmo e seu uso."
JP5502397B2 (ja) * 2009-08-25 2014-05-28 公益財団法人微生物化学研究会 新規化合物アミコロース誘導体、並びにその製造方法及びその用途
CN103420902A (zh) * 2012-05-18 2013-12-04 苏州爱斯鹏药物研发有限责任公司 一种2-氯-4-碘-5-甲基吡啶的制备方法
US20160024098A1 (en) 2013-03-15 2016-01-28 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
CN103193704B (zh) * 2013-04-12 2016-03-09 四川铂瑞生物医药有限公司 2-羟基-4-氨基-5-甲基吡啶杂环化合物
US20160264536A1 (en) * 2013-10-23 2016-09-15 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP4088719A1 (en) 2015-10-13 2022-11-16 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
US12048761B2 (en) 2015-10-13 2024-07-30 Inserm (Institut National De La Santé Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
US20190073895A1 (en) * 2017-09-07 2019-03-07 Timetec Holding Sdn Bhd Alarm system
CN113474332B (zh) 2019-03-05 2025-03-04 拜耳公司 合成4-氨基-5-甲基-1h-吡啶-2-酮的方法
CN113929591A (zh) * 2021-10-09 2022-01-14 中国科学技术大学 具有抗增殖活性的抑制剂
CN117024335A (zh) * 2023-07-10 2023-11-10 杭州小蓓医药科技有限公司 一种非奈利酮中间体4-氨基-5-甲基-1h-吡啶-2(i)-酮的合成工艺
WO2025224050A1 (en) 2024-04-22 2025-10-30 Institut National de la Santé et de la Recherche Médicale Methods of treatment of patients suffering from hypomelanosis of ito

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1274295A (en) * 1993-12-30 1995-07-17 Ciba-Geigy Ag Heteroarylpyrroles
US5776954A (en) * 1996-10-30 1998-07-07 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
KR20010111298A (ko) * 2000-02-05 2001-12-17 버텍스 파마슈티칼스 인코포레이티드 Ｅｒｋ의 억제제로서 유용한 피라졸 조성물
US7304061B2 (en) * 2002-04-26 2007-12-04 Vertex Pharmaceuticals Incorporated Heterocyclic inhibitors of ERK2 and uses thereof
ZA200504898B (en) 2002-12-20 2006-11-29 Pharmacia Corp Acyclic pyrazole compounds
JP2006518381A (ja) 2003-02-07 2006-08-10 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用なヘテロアリール置換ピロール
UA84930C2 (ru) * 2004-05-14 2008-12-10 Вертекс Фармасьютикалс Инкорпорейтед Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения

Similar Documents

Publication Publication Date Title
JP2007530595A5 (https=)
US9440961B2 (en) Rho-kinase inhibitors and method of preparation
CN1113066C (zh) 新型肽衍生物
JP2001517699A5 (https=)
JP2003522163A5 (https=)
JP2010532380A5 (https=)
JP2006520386A5 (https=)
CA2755095A1 (en) Rho kinase inhibitors
CN1161330A (zh) 取代的间二氮杂萘衍生物
JP2006522124A5 (https=)
CN116457344A (zh) 低分子量蛋白质降解剂及其应用
JP2008528671A5 (https=)
EA015779B1 (ru) Соединения для ингибирования митоза
RU2009102243A (ru) Производные камптотецина с противоопухолевой активностью
WO2016160980A1 (en) Methods of administering glutaminase inhibitors
JP4930055B2 (ja) 抗腫瘍剤
JP2017214420A5 (https=)
RU2362579C1 (ru) Фармацевтическая композиция на основе пептида, обладающего противоопухолевым действием
US8957103B2 (en) Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
JP6785801B2 (ja) 新しいキャップ基ラルガゾールの類似体の合成及び使用
JP2014055136A (ja) 薬物動態が改善された化合物
US12357612B2 (en) Prophylactic or therapeutic agent for cancer
JP2002503674A5 (https=)
ES2877809T3 (es) Terapia combinada para enfermedades proliferativas
ES2222988T3 (es) Formas de sal especificas de derivados de trifeniletileno como moduladores selectivos de los receptores de estrogenos.